Grants per year
Search results
-
Finished
Prot#CIN-107-122 : A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of CIN-107 for the Treatment of Patients With Primary Aldosteronism (PA)
Huang, W. (PD/PI)
Medpace Clinical Research LLC, AstraZeneca PLC
2/9/22 → 2/9/25
Project: Research project
-
Prot# SPR001-203: A Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia"
Huang, W. (PD/PI)
Medpace Clinical Research LLC, Spruce Biosciences, Inc.
8/25/21 → 12/31/24
Project: Research project
-
Protocol TCH-306:A multicenter, randomized,parallel-arm, placebo-controlled(double blind) and active-controlled(open-label) trial to compare the efficacy and safety of once-weekly lonapegsomatropin with placebo and daily somatropin product in adults with
Huang, W. (PD/PI)
Accelsiors CRO and Consultancy Services Ltd., Ascendis Pharma A/S
6/9/21 → 8/31/24
Project: Research project
-
Prot#OOC-ACM-RGI: The Management of Acromegaly (MACRO) Registry
Huang, W. (PD/PI)
9/25/20 → 8/31/24
Project: Research project
-
Prot#ISIS 766720-CS3: An Open-Label Extension Trial of IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor administered monthly subcutaneously to Patients with Acromegaly Being Treated with Long-acting Somatostatin Receptor Ligands (SRL)"
Huang, W. (PD/PI)
Medpace Clinical Research LLC, Ionis Pharmaceuticals, Inc.
9/23/20 → 9/23/23
Project: Research project
-
Prot#CORT125134-455: Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant
Huang, W. (PD/PI)
ICON Clinical Research Limited, Corcept Therapeutics Incorporated
9/25/19 → 9/25/22
Project: Research project
-
Prot#CRN00808-02: A Double-blind, Placebo-controlled, Randomized Withdrawal Study to Evaluate the Safety, Pharmacokinetics and Efficacy of CRN00808 in Patients with Acromegaly that are Responders to Octreotide Lar or Landreotide (ACROBAT EVOLVE)
Huang, W. (PD/PI) & Molitch, M. E. (Other)
Accelsiors CRO and Consultancy Services Ltd., Crinetics Pharmaceuticals, Inc.
8/6/19 → 8/6/22
Project: Research project
-
Prot#CRN00808-03: An Open Label Exploratory Study to Evaluate the Safety, Pharmacokinetics and Efficacy of CRN00808 in Patients with Acromegaly Treated with Somatostatin Analogue Based Treatment Regimens (ACROBAT EDGE)
Huang, W. (PD/PI) & Molitch, M. E. (Other)
Accelsiors CRO and Consultancy Services Ltd., Crinetics Pharmaceuticals, Inc.
8/6/19 → 8/6/22
Project: Research project
-
Prot#CLCI699C2X01B: An Open-label, Multi-Center, Roll-Over Study to Assess Long Term Safety in Patients with Endogenous Cushing’s Syndrome Who Have Completed a Prior Novartis-Sponsored Osilodrostat (LCI699) Study and are Judged by the Investigator to Bene
Huang, W. (PD/PI) & Molitch, M. E. (Other)
Novartis Pharmaceuticals Corporation
5/22/19 → 12/31/24
Project: Research project
-
Prot#: ISIS 766720-CS2: A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor) Administered Once Every 28 Days for 16 Weeks i
Huang, W. (PD/PI) & Molitch, M. E. (Other)
Medpace Clinical Research LLC, Ionis Pharmaceuticals, Inc.
4/3/19 → 4/3/22
Project: Research project
-
Prot#COR-2017-01:A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Huang, W. (PD/PI) & Molitch, M. E. (Other)
Chiltern International, Inc., Cortendo AB (publ)
4/24/18 → 4/24/21
Project: Research project
-
Prot# OOC-ACM-302: A Phase 3, Randomized, Open-Label, Active Controlled, Multicenter Study to Evaluate Maintenance of Response, Safety and Patient Reported Outcomes in Acromegaly Patients Treated with Octreotide Capsules, and in Patients Treated with Stan
Huang, W. (PD/PI) & Molitch, M. E. (Other)
Pharm-Olam International Ltd., Chiasma, Inc.
3/18/16 → 1/24/22
Project: Research project
-
Prot #16244: A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multicenter, Event-Driven Phase III Study to Investigate the Efficacy and Safety of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Subjects
Huang, W. (PD/PI), Batlle, D. (Co-Investigator), Wallia, A. (Co-Investigator) & Molitch, M. E. (Other)
Bayer HealthCare Pharmaceuticals, Inc.
1/5/16 → 5/31/20
Project: Research project
-
LCI699C2301, entitled " A Phase III, Multi-Center Double-Blind, Randomized, Withdrawal Study of LCI699 Following a 24 Week, Single-Arm, Open-Label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patie
Huang, W. (PD/PI) & Molitch, M. E. (Other)
Novartis Pharmaceuticals Corporation
6/20/14 → 6/30/20
Project: Research project
-
Prot #CLCI699C2201: A Proof-of Concept, Open-Label, Forced Titration, Multi-Center Study to Assess the Safety/Tolerability and Efficacy of 10-Weeks Treatment of LCI699 Followed by a 12 Week Treatment Period in Patients with Cushing's Disease.
Huang, W. (PD/PI), Wallia, A. (Co-PD/PI) & Molitch, M. E. (Other)
Novartis Pharmaceuticals Corporation
1/1/12 → 10/31/20
Project: Research project
-
Neuroendocrine Regulation of GnRH Release
Huang, W. (Other)
National Institute of Child Health and Human Development
4/1/02 → 3/31/07
Project: Research project